May 15 (Reuters) - Protara Therapeutics Inc TARA.O:

• PROTARA THERAPEUTICS ANNOUNCES POSITIVE UPDATED 12-MONTH DATA DEMONSTRATING DURABLE RESPONSES IN THE FULLY ENROLLED BCG-NAÏVE COHORT OF THE ONGOING PHASE 2 ADVANCED-2 TRIAL OF TARA-002 IN NMIBC

• PROTARA THERAPEUTICS: TARA-002 DEMONSTRATES 72% COMPLETE RESPONSE RATE AT ANY TIME, 67% COMPLETE RESPONSE RATE AT 6-MONTH LANDMARK

• PROTARA THERAPEUTICS INC: TARA-002 DEMONSTRATES 55% COMPLETE RESPONSE RATE AT 12-MONTH LANDMARK

• PROTARA THERAPEUTICS INC: TARA-002 SHOWED FAVORABLE SAFETY AND TOLERABILITY PROFILE

• PROTARA THERAPEUTICS INC: ON TRACK TO INITIATE ADVANCED-3 REGISTRATIONAL TRIAL IN BCG-NAÏVE PATIENTS IN 2H 2026

Source text: ID:nGNX7hsP38

Further company coverage: TARA.O